| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.5 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.5 |